Celltrion partners with US pharmacy chain for Yuflyma sales
Celltrion Healthcare, Celltrion's distribution unit, said Monday it has signed a deal with US specialty pharmacy chain CarePartners Pharmacy to sell its Humira biosimilar Yuflyma in the US market.
CarePartners Pharmacy is a national pharmacy that distributes medications across all 50 states and Washington DC, focusing on several niche programs, including autoimmune therapies.
Under the contract, Yuflyma will be distributed to drug stores operated by CarePartners Pharmacy nationwide, starting from the end of this month.
Celltrion said the partnership is expected to raise the presence of the Yuflyma autoimmune disease biosimilar among over 10 million patients in the US.
Yuflyma will be the only adalimumab sold at CarePartners Pharmacy drugstores as the US partner has decided not to sell AbbVie's blockbuster drug Humira and other competing biosimilars in the market.
Celltrion said it could ink the exclusive contract due to the drug's convenience both for patients and health care providers.
“Yuflyma uses a high concentration, citrate-free formulation, causing less pain when injected. The medication also comes with a latex-free injectable device, which can reduce allergy risk,” an official from Celltrion said.
Meanwhile, Celltrion Healthcare said the company will tap pharmacy benefit managers (PBMs), including Optum, to enlist Yuflyma in their formulary lists.
PBMs are companies that manage prescription drug benefits on behalf of health insurers. They negotiate fees and rebates with drug providers and create formulary lists of medications covered by insurance and reimburse pharmacies for patients' prescriptions.
Celltrion Healthcare said the company will increase its marketing efforts, with a goal of capturing around 40 percent share in the PBM market for adalimumab by the end of this year.
(责任编辑:뉴스)
下一篇:GOT7’s Youngjae to release 1st solo LP “Do It” next month
- ·Tving streams 2023 MTV VMAs
- ·Jungkook of BTS sweeps iTunes’ Top Songs charts in 100 different regions
- ·Chuseok’s celestial journey: Best spots for full moon gazing in Seoul
- ·Memorials commemorating Itaewon crowd crush to be erected at accident site
- ·Whisky imports surge 40% through August, suggesting record
- ·GOT7’s Youngjae to release 1st solo LP “Do It” next month
- ·Golden apples: Why fruit prices are national issue in early autumn
- ·Allies vow stern measures against Russia
- ·[New in Korean] Ancient Korean mummy unearthed in Irish peatland
- ·[Our Museums] Discover wisdom of hanok at Eunpyeong History Hanok Museum
- ·Ministry uncovers 1,802 Youth Protection Act violations
- ·Ministry uncovers 1,802 Youth Protection Act violations
- ·Sabre fencer, swimming relay team eye historic medals
- ·Gimbap and hanja cramming: Life of Korean Studies students in Paris
- ·[Herald Interview] Jung Soo
- ·이준석, 눈물의 회견…尹대통령 향해 "與 묵언 수행 저주 풀라"
- ·Gangwon Forestry Exhibition 2023 kicks off in Korea's 'forest capital'
- ·PM arrives in China for Asian Games, meeting with Xi
- ·[Today’s K
- ·[Herald Interview] Netflix's ‘Devil’s Plan’ expands realm of survival game shows
- ·Outpaced by Coupang, Shinsegae carries out major leadership reshuffle
- ·KFCC promotes financial inclusion via branches in developing nations
- ·[Herald Interview] ‘Another Body,’ a riveting documentary on devasting effects of deepfake porn
- ·[Korea Beyond Korea] In Paris, soaring demand for Korean studies yet to be fully met
- ·[Herald Interview] ‘Another Body,’ a riveting documentary on devasting effects of deepfake porn